Savant Capital LLC Sells 87,677 Shares of DexCom, Inc. $DXCM

Savant Capital LLC trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 78.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,725 shares of the medical device company’s stock after selling 87,677 shares during the quarter. Savant Capital LLC’s holdings in DexCom were worth $2,071,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of DXCM. Vanguard Group Inc. grew its stake in shares of DexCom by 2.0% in the first quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company’s stock worth $3,240,763,000 after purchasing an additional 925,882 shares during the last quarter. Jennison Associates LLC raised its position in DexCom by 9.4% during the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after purchasing an additional 994,300 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in DexCom by 22.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock worth $691,336,000 after buying an additional 1,868,241 shares during the period. Nuveen LLC bought a new stake in shares of DexCom in the 1st quarter valued at about $554,893,000. Finally, Raymond James Financial Inc. grew its position in shares of DexCom by 21.8% in the 1st quarter. Raymond James Financial Inc. now owns 3,355,057 shares of the medical device company’s stock valued at $229,117,000 after buying an additional 601,088 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the topic of a number of recent analyst reports. Morgan Stanley cut their price objective on DexCom from $89.00 to $63.00 and set an “equal weight” rating on the stock in a research note on Monday. Wells Fargo & Company set a $93.00 price target on shares of DexCom and gave the stock an “overweight” rating in a report on Friday, October 31st. Citigroup reduced their price objective on shares of DexCom from $85.00 to $75.00 and set a “buy” rating on the stock in a research note on Friday, October 31st. Truist Financial reissued a “buy” rating and set a $82.00 target price (down previously from $94.00) on shares of DexCom in a research note on Monday, November 3rd. Finally, TD Cowen dropped their target price on shares of DexCom from $100.00 to $84.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, DexCom has an average rating of “Moderate Buy” and an average price target of $87.62.

Insider Transactions at DexCom

In other news, COO Jacob Steven Leach purchased 18,200 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The shares were acquired at an average cost of $55.04 per share, with a total value of $1,001,728.00. Following the purchase, the chief operating officer owned 331,697 shares in the company, valued at $18,256,602.88. This represents a 5.81% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Richard Alexander Collins sold 3,948 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $55.17, for a total value of $217,811.16. Following the completion of the transaction, the director owned 37,994 shares in the company, valued at approximately $2,096,128.98. The trade was a 9.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 9,331 shares of company stock valued at $652,085. 0.32% of the stock is owned by insiders.

DexCom Price Performance

DexCom stock opened at $58.13 on Wednesday. The stock has a market capitalization of $22.67 billion, a price-to-earnings ratio of 40.37, a PEG ratio of 1.43 and a beta of 1.40. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $93.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The stock’s 50 day moving average price is $68.51 and its two-hundred day moving average price is $77.51.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.45 EPS. DexCom has set its FY 2025 guidance at EPS. On average, equities analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.